



3-30-06

JPW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/753,289	
	Filing Date	January 5, 2004	
	First Named Inventor	Steven M. WATKINS	
	Art Unit	1631	
	Examiner Name	M. Moran	
Total Number of Pages in This Submission	8 + 20 Refs.	Attorney Docket Number	475512000100

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (Supplemental - 3 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Form PTO/SB/08a/b + copy (4 pages) 2. Twenty (20) References 3. Return Receipt Postcard
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	MORRISON & FOERSTER LLP (Customer No. 25226)		
Signature			
Printed name	Alicia J. Hager		
Date	March 28, 2006	Reg. No.	44,140

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 596702369 US, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: March 28, 2006	Signature: (Georgina Matos)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 596702369 US, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 28, 2006

Signature:

Georgia Matos
(Georgia Matos)

Patent

Docket No. 475512000100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Steven M. WATKINS

Serial No.: 10/753,289

Filing Date: January 5, 2004

For: GENERATING, VIEWING,
INTERPRETING, AND UTILIZING A
QUANTITATIVE DATABASE OF
METABOLITES

Examiner: M. Moran

Group Art Unit: 1631

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of a foreign publication and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.

- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
- ☐ A fee is required. A check in the amount of __ is enclosed.
- ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicant would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petition and/or other

Application Serial No. 10/753,289


Patent
Docket No. 475512000100

fees due in connection with the filing of this document to **Deposit Account No. 03-1952**
referencing 475512000100.

Dated: March 28, 2006

Respectfully submitted,

By


Alicia J. Hager

Registration No.: 44,140

MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304-1018
(650) 813-4296



ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/753,289
				Filing Date	January 5, 2004
				First Named Inventor	Steven M. WATKINS
				Art Unit	1631
				Examiner Name	M. Moran
				Attorney Docket Number	475512000100
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1.	US-2003/0023386-A1	01-30-2003	Aranibar et al.	
	2.	US-6,423,540-B2	07-23-2002	Baur et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)				
	3.	WO-03/005628-A2,A3	01-16-2003	Lipomics Technologies, Inc.		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	4.	Boersma, M.G. et al. (January/February 2001). " ¹⁹ F NMR Metabolomics for the Elucidation of Microbial Degradation Pathways of Fluorophenols," <i>J. Ind. Microbial. Biotechnol.</i> 26(1/2):22-34.	
	5.	Gates, S.C. et al. (1978). "Quantitative Metabolic Profiling Based on Gas Chromatography," <i>Clinical Chem.</i> 24(10):1663-1673.	
	6.	Griffin, J.L. et al. (June 1, 2001). "Metabolic Profiling of Genetic Disorders: A Multitissue ¹ H Nuclear Magnetic Resonance Spectroscopic and Pattern Recognition Study into Dystrophic Tissue," <i>Anal. Biochem.</i> 293(1):16-21.	
	7.	International Preliminary Examination Report mailed November 29, 2005 for PCT Application No. PCT/US02/21426 filed July 5, 2002, seven pages.	
	8.	International Search Report mailed August 18, 2003 for PCT Application No. PCT/US02/21426 filed July 5, 2002, six pages.	
	9.	Jardine, A. et al. (December 1999). "Fluvastatin in Combination with Cyclosporin in Renal Transplant Recipients: A Review of Clinical and Safety Experience," <i>J. Clinical Pharmacy and Therapeutics</i> 24(6):397-408.	
	10.	Lithell, H. (1993). "Hypertension and Hyperlipidemia: A Review," <i>Am. J. of Hypertension</i> 6(11):303S-308S.	
	11.	Raamsdonk, L.M. et al. (January 2001). "A Functional Genomics Strategy That Uses Metabolome Data to Reveal the Phenotype of Silent Mutations," <i>Nature Biotechnology</i> 19:45-50.	
	12.	Saudek, C.D. et al. (May 1979). "Lipid Metabolism in Diabetes Mellitus," <i>Am. J. Med.</i> 66(1):843-852.	
	13.	Siguel, E.N. et al. (July 1987). "Relative Activity of Unsaturated Fatty Acid Metabolic Pathways in Humans," <i>Metabolism</i> 36(7):664-669.	
	14.	Siguel, E.N. et al. (September 1986). "Monitoring the Optimal Infusion of Intravenous Lipids. Detection of Essential Fatty Acid Deficiency," <i>Arch. Pathol. Lab. Med.</i> 110(9):792-797.	
	15.	Tanaka, K. et al. (April 30, 1982). "Compilation of Gas Chromatographic Retention Indices of 163 Metabolically Important Organic Acids and Their Use in Detection of Patients with Organic	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

pa- 1048021

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/753,289
				Filing Date	January 5, 2004
				First Named Inventor	Steven M. WATKINS
				Art Unit	1631
				Examiner Name	M. Moran
Sheet	2	of	2	Attorney Docket Number	475512000100

		Acidurias," <i>J. Chromatogr.</i> 239:301-322.	
	16.	Tate, A.R. et al. (May-June 1996). "Lipid Metabolite Peaks in Pattern Recognition Analysis of Tumour <i>in Vivo</i> MR Spectra," <i>Anticancer Res.</i> 16(3B):1575-1579.	
	17.	Toft, P.B. et al. (January/February 1994). "T1, T2, and Concentrations on Brain Metabolites in Neonates and Adolescents Estimated with H-1 MR Spectroscopy," <i>Journal of Magnetic Resonance Imaging</i> 4(1):1-5.	
	18.	Tweeddale, H. et al. (October 1998). "Effect of Slow Growth of Metabolism of <i>Escherichia coli</i> , as Revealed by Global Metabolite Pool ("Metabolome") Analysis," <i>J. Bacteriol.</i> 180(19):5109-5116.	
	19.	Vigneau-Callahan, K.E. et al. (March 2001). "Characterization of Diet-Dependent Metabolic Serotypes: Analytical and Biological Variability Issues in Rats," <i>J. Nutr.</i> 131(3):924S-932S.	
	20.	Waters, N.J. et al. (July 1, 2002). "NMR and Pattern Recognition Studies on Liver Extracts and Intact Livers from Rats Treated with α -Naphthylisothiocyanate," <i>Biochem. Pharm.</i> 64(1):67-77.	
	21.	Watkins, S.M. (September 2000). "Comprehensive Lipid Analysis: A Powerful Metanomic Tool for Predictive and Diagnostic Medicine," <i>IMAJ</i> 2(9):722-724.	
	22.	Witten, T.A. et al. (1973). "Gas-Chromatographic-Mass-Spectrometric Determination of Urinary Acid Profiles of Normal Young Adults on a Controlled Diet," <i>Clinical Chem.</i> 19(6):586-589.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--